Estimation and construction of confidence intervals for biomarker cutoff‐points under the shortest Euclidean distance from the ROC surface to the perfection corner

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer with a 5‐year survival rate of less than 5%. As in many other diseases, its diagnosis might involve progressive stages. It is common that in biomarker studies referring to PDAC, recruitment involves three groups: healthy individ...

Full description

Saved in:
Bibliographic Details
Published inStatistics in medicine Vol. 40; no. 20; pp. 4522 - 4539
Main Authors Mosier, Brian R., Bantis, Leonidas E.
Format Journal Article
LanguageEnglish
Published England 10.09.2021
Subjects
Online AccessGet full text
ISSN0277-6715
1097-0258
1097-0258
DOI10.1002/sim.9077

Cover

More Information
Summary:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer with a 5‐year survival rate of less than 5%. As in many other diseases, its diagnosis might involve progressive stages. It is common that in biomarker studies referring to PDAC, recruitment involves three groups: healthy individuals, patients that suffer from chronic pancreatitis, and PDAC patients. Early detection and accurate classification of the state of the disease are crucial for patients' successful treatment. ROC analysis is the most popular way to evaluate the performance of a biomarker and the Youden index is commonly employed for cutoff derivation. The so‐called generalized Youden index has a drawback in the three‐class case of not accommodating the full data set when estimating the optimal cutoffs. In this article, we explore the use of the Euclidean distance of the ROC to the perfection corner for the derivation of cutoffs in trichotomous settings. We construct an inferential framework that involves both parametric and nonparametric techniques. Our methods can accommodate the full information of a given data set and thus provide more accurate estimates in terms of the decision‐making cutoffs compared with a Youden‐based strategy. We evaluate our approaches through extensive simulations and illustrate them on a PDAC biomarker study.
Bibliography:Funding information
National Institute of Health, COBRE / P20GM130423; Clinical & Translational Science Award/UL1TR002366; NIH Clinical and Translational Science Award, UL1TR002366
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
3901 Rainbow Blvd., Kansas City, KS 66160
Present Address
ISSN:0277-6715
1097-0258
1097-0258
DOI:10.1002/sim.9077